According to the most recent UN estimate made public by the United Nations Inter-agency Group for Child Mortality Estimation, 2.1 million children and youth aged between 5 and 24 years and 5 million children and youth under the age of five died in 2021.
Acute malnutrition affects more than 30 million children in the 15 countries that are most severely affected. Severe wasting, the deadliest form of undernutrition, affects 8 million of these children. This poses a serious risk to children’s lives, long-term health, and development, and it has an effect on every person, every community, and every nation.
9 January (Reuters) AstraZeneca (AZN.L) declared on Monday that it has reached an agreement to acquire American drug-development company CinCor Pharma Inc (CINC.O) for up to $1.8 billion in order to expand its supply of heart and kidney medications.
The experimental medication baxdrostat, which is being developed by CinCor to treat illnesses like high blood pressure and chronic renal disease, is at the heart of the agreement.
COVID-19: According to Serum Institute of India CEO Adar Poonawalla, Covovax would be approved as a booster in 10 to 15 days
Adar Poonawalla, chief executive officer of Serum Institute of India, stated on Sunday that the Covovax vaccine will be approved as a booster in the upcoming 10 to 15 days and added that it is effective against the Omicron form of coronavirus.
By 2030, the goal of the collaboration will be to provide 10,000 patients their own mRNA. A partnership between BioNTech and the UK government has been announced with the objective of hastening the development of individualized mRNA immunotherapies.
Bharat Biotech, an Indian vaccine manufacturer, said on Friday that the Russia-Ukraine crisis had so far had no impact on its supply lines
The collaboration campaign provides educational materials and other resources for individuals with certain types of breast cancers and their care partners.
Lupin has launched Sevelamer Hydrochloride tablets (800 mg) in the US market to treat hyperphosphatemia in patients with chronic kidney disease. After receiving approval from the US Food and Drug Administration, the company launched the product (USFDA).
The agency has asked Amryt to submit additional data confirming effectiveness of the drug.
Vonjo (pacritinib) belongs to a class of anti-inflammatory drugs known as JAK inhibitors, and it will compete with Incyte Corp’s Jakafi and Bristol Myers’ Inrebic, which were authorised for treating Myelofibrosis in 2011 and 2019, respectively